Cargando…
Exposure–Response Modeling of Clinical End Points Using Latent Variable Indirect Response Models
Exposure–response modeling facilitates effective dosing regimen selection in clinical drug development, where the end points are often disease scores and not physiological variables. Appropriate models need to be consistent with pharmacology and identifiable from the time courses of available data....
Autor principal: | Hu, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076802/ https://www.ncbi.nlm.nih.gov/pubmed/24897307 http://dx.doi.org/10.1038/psp.2014.15 |
Ejemplares similares
-
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
por: Mould, DR, et al.
Publicado: (2015) -
Modeling Composite Assessment Data Using Item Response Theory
por: Ueckert, Sebastian
Publicado: (2018) -
Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development
por: Overgaard, RV, et al.
Publicado: (2015) -
Frequency‐Domain Response Analysis for Quantitative Systems Pharmacology Models
por: Schulthess, Pascal, et al.
Publicado: (2017) -
Many Flavors of Model‐Based Meta‐Analysis: Part II – Modeling Summary Level Longitudinal Responses
por: Boucher, Martin, et al.
Publicado: (2018)